How significant is the role of P-glycoprotein in drug absorption and brain uptake?

Drugs of Today

Volumn 40, Issue 1, 2004, Pages 5-22

  Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CETIRIZINE; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN A; DEXAMETHASONE; DICLOXACILLIN; DIGOXIN; DIPYRIDAMOLE; ELETRIPTAN; ETOPOSIDE; GLYCOPROTEIN P; INDINAVIR; IVERMECTIN; LEVOFLOXACIN; LOSARTAN; NELFINAVIR; PACLITAXEL; PREDNISOLONE; PROTEINASE INHIBITOR; QUINIDINE; RIFAMPICIN; RITONAVIR; TACROLIMUS; TALINOLOL; TRIMETHOPRIM; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; AREA UNDER THE CURVE; BRAIN CAPILLARY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG UPTAKE; ENDOTHELIUM CELL; HUMAN; INTESTINE ABSORPTION; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; HUMANS; INTESTINAL ABSORPTION; P-GLYCOPROTEIN;

EID: 1442301563     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.1.799434     Document Type: Review

References (106)

1. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., Willingham, M.C. Cellular localization of the multidrug resistance gene product p-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84: 7735-8.
2. Cordon-Cardo, C., O'Brien, J.P., Boccia, J., Bertino, J.R., Melamed, M.R. Expression of the multidrug resistance gene product (p-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990, 38: 1277-87.
3. Lin, J.H., Yamazaki, M. Role of p-glycoprotein in pharmacokinetic: Clinical implications. Clin Pharmacokinet 2003, 42: 59-98.
4. Benet, L.Z., Wu, C.Y., Hebert, M.F., Wacher, V.J. Intestinal drug metabolism and anti-transport processes: A potential paradigm shift in oral drug delivery. J Control Release 1996, 39: 139-43.
5. Benet, L.Z., Cummins, C. The drug efflux-metabolism alliance: Biochemical aspects. Adv Drug Del Rev 2001, 50: S3-S11.
6. Tamai, I., Tsuji, A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000, 89: 1371-88.
7. Sun, H., Dai, H., Shaik, N., Elmquist, W.F. Drug efflux transporters in the CNS. Adv Drug Del Rev 2003, 55: 83-105.
8. Wilson, C.G., Washington, N. Small intestine: Transit and absorption of drugs. In: Physiological Pharmaceutics: Biological Barriers to Drug Absorption. Wilson, C.G., Washington, N. (Eds.). Ellis Horwood, Ltd., Chichester 1989, 71-90.
9. Macey, R.I. Mathematical models of membrane transport processes. In: Physiology of Membrane Disorders. Andreoli, R. (Ed.). Plenum Press, New York 1978, 125-46.
10. Pade, V., Stavchansky, S. Estimation of the relative contribution of transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res 1997, 14: 1210-5.
11. Artursson, P., Palm, K., Luthman, K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Delivery Rev 1996, 22: 67-84.
12. Hidalgo, I.J., Raub, T.J., Borchardt, R.T. Characterization of human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 96: 736-49.
13. Artursson, P., Karlsson, J. Correlation between drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991, 175: 880-5.
14. Irvine, J.D., Takahashi, L., Lockhart, K. et al. MDCK (Madin-Darby Canine Kidney) cells: A tool for membrane permeability screening. J Pharm Sci 1999, 88: 28-33.
15. Hunter, J., Jepson, M.A., Tsuruo, T., Simmons, N.L., Hirst, B.H. Functional expression of p-glycoprotein in apical membranes of human intestinal Caco-2 cell layers: Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 1993, 268: 14991-7.
16. Hunter, J., Hirst, B.H., Simmons, N.L. Drug absorption limited by p-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cells. Pharm Res 1993; 10: 743-9.
17. Augustijins, P.F., Bradshaw, T.P., Gan, L.S.L., Hendren, D.R., Thakker, D.R. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport. Biochem Biophys Res Commun 1993, 197: 360-365.
18. Burton, P.S., Conaradi, R.A., Hilgers, A.R., Ho, N.F.H. Evidence for a polarized efflux for peptides in the apical membrane of Caco-2 cells. Biochem Biophys Res Commun 1993, 190: 760-6.
19. Sparreboom, A., van Asperen, J., Mayer, U. et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by p-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997, 94: 2031-5.
20. Mayer, U., Wagnaar, E., Beijnen, J.H. et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a p-glycoprotein. Br J Pharmacol 1996; 119: 1038-44.
21. Su, F.G., Huang, J.D. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996, 24: 142-7.
22. Drescher, S., Glaeser, H., Murdter, T., Hitzl, M., Eichelbaum, M., Fromm, M.F. P-glycoprotein-mediated intestinal and biliary transport in humans. Clin Pharmacol Ther 2003, 73: 223-31.
23. Gramatte, T., Oertel, R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 1999, 66: 239-45.
24. Meerum Terwgot, J.M., Malingre, M.M., Beijnen, J.H. et al. Co-administration of cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999, 5: 3379-84.
25. Dantzig, A.H., de Alwis, D.P., Burgess, M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Delivery Rev 2003, 55: 133-50.
26. Bohme, M., Buchler, M., Muller, M. et al. Differential inhibition by cyclosporines of primary-active ATP-dependent transporters in hepatocyte canalicular membrane. FEBS Lett 1993, 333: 193-6.
27. Sonnichsen, D.S., Liu, Q., Schuetz, E.G., Schuetz, J.D., Pappo, A., Relling, M.V. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995, 275: 566-75.
28. Hoffmeyer, S., Burk, O., von Richter, O. et al. Functional polymorphisms of the human multidrug resistance gene: Multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
29. Lown, K.S., Mayo, R.R., Leichtman, A.B. Role of intestinal p-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997, 62: 248-60.
30. Fricker, G., Drewe, J., Huwyler, J., Gutmann, H., Beglinger, C. Relevance of p-glycoprotein for the enteral absorption of cyclosporine A: In vitro-in vivo correlation. Br. J. Pharmacol. 1996; 118: 1841-1847.
31. Fojo, A.T., Ueda, K., Slamon, D.J., Pollack, D.G., Gottesman, M.M., Pastan, I. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84: 265-9.
32. Stephens, R.H., O'Neill, C.A., Warhurst, A., Carlson, L., Rowland, M., Warhurst, G. Kinetic profiling of p-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001, 296: 584-91.
33. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Komano, T. Human p-glycoprotein transports cyclosporine A and FK506. J Biol Chem 1993; 268: 6077-80.
34. Hochman, J.H., Chiba, M., Yamazaki, M., Tang, C., Lin, J.H. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. J Pharmacol Exp Ther 2001, 298: 323-30.
35. Wetterich, U., Spahn-Langguth, H., Mutschler, E., Terhaag, B., Rosch, W., Langguth, P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 1996, 13: 514-22.
36. Ueda, C.T., Lemaire, M., Gsell, G. et al. Apparent dose dependent oral absorption of cyclosporine A in rats. Biopharm Drug Dispos 1984; 5: 141-51.
37. Ooi, H., Colucci, W.S. Pharmacological treatment of heart failure. In: Goodman & Gilman's. The Pharmacological Basis of Therapeutics (tenth ed.). Hardamn, J.G., Limbird, L.E. (Eds.). McGraw-Hill, New York 2001, Chapter 34, 901-32.
38. Raffanti, S., Haas, D.W. Antiretroviral agents. In: Goodman & Gilman's. The Pharmacological Basis of Therapeutics (tenth ed.). Hardamn, J.G., Limbird, L.E. (Eds.). McGraw-Hill, New York 2001, Chapter 51: 1349-80.
39. Ueda, C.T., Williamson, B.J., Dzindzio, B.S. Absolute quinidine bioavailability. Clin Pharmacol Ther 1976, 20: 260-5.
40. Polli, J.W., Wring, S.A., Humphreys, J.E. et al. Rational use of in vitro p-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001, 299: 620-8.
41. McTavish, D., Sorkin, E.M. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1989, 38: 19-76.
42. Greiner, B., Eichelbaum, M., Fritz, P. et al. The role of intestinal p-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999, 104: 147-53.
43. Westphal, K., Weinbrenner, A., Zschiesche, M. et al. Induction of p-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction. Clin Pharmacol Ther 2000, 68: 345-55.
44. Backman, J.T., Olkkola, K.T., Neuvonen, P.J. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996, 59: 7-13.
45. Kovarik, J.M., Rigaudy, L., Guerret, M., Gerbeau, C., Rost, K.L. Longitudinal assessment of a p-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 1999, 66: 391-400.
46. Wandel, C., Kim, R.B., Guengerich, F.P., Wood, A.J. Mibefradil is a p-glycoprotein substrate and a potent inhibitor of both p-glycoprotein and CYP3A in vitro. Drug Metab Dispos 2000, 28: 895-8.
47. Verstuyft, C., Strabach, S., El Morabet, H. et al. Dipyridamole enhances digoxin bioavailability via p-glycoprotein inhibition. Clin Pharmacol Ther 2003, 73: 51-60.
48. Olkkola, K.T., Backman, J.T., Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994, 55: 481-5.
49. Brightman, M.W. The anatomic basis of the blood-brain barrier. In: Implications of the Blood-Brain Barrier and its Manipulation: Basic Science Aspects, vol. 1. Neuwelt, E.A. (Ed.).Plenum, New York 1988, Chapter 3: 53-83.
50. Johanson, C.E. Potential for pharmacologic manipulation of the blood-cerebrospinal fluid barrier. In: Implications of the Blood-Brain Barrier and its Manipulation: Basic Science Aspects, vol. 1. Neuwelt, E.A. (Ed.).Plenum, New York 1988, Chapter 9: 223-60.
51. Pardridge, W.M. Transport of protein-bound hormones into tissue in vivo. Endocr Rev 1981, 2: 103-23.
52. Rapoport, S.I. Transport in cells and tissues. In: Rapport, S.I. (Ed.). Blood-brain Barrier in Physiology and Medicine. Raven Press, New York 1976, 17-42.
53. Levin, V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980, 23: 682-4.
54. Lin, T.H., Lin, J.H. Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats. J Pharmacol Exp Ther 1990, 253: 45-50.
55. Chikhale, E.G., Ng, K.Y., Burton, P.S., Borchardt, R.T. Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm Res 1994, 11: 412-9.
56. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., Willingham, M.C. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989, 37: 159-64.
57. Cordon-Cardo, C., O'Brien, J.P., Casals, D. et al. Multidrug-resistance gene (p-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-8.
58. Jette, L., Tetu, B., Beliveau, R. High levels of p-glycoprotein detected in isolated brain capillaries. Biochem Biophys Acta 1993, 1150: 147-54.
59. Tsuji, A., Terasaki, T., Takabatake, Y. P-glycoprotein as the drug efflux pump in the primary cultured bovine brain capillary endothelial cells. Life Sci 1992, 51: 1427-37.
60. Hegmann, E.J., Bauer, H.C., Kerbel, R.S. Expression and functional activity of p-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res 1992, 52: 6969-75.
61. Pardridge, W.M., Golden, P.L., Kang, Y.S., Bickel, U. Brain microvascular and astrocyte localization of p-glycoprotein. J Neurochem 1997, 68: 1278-85.
62. Golden, P.L., Pardridge, W.M. P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res 1999, 819: 143-6.
63. Golden, P.L., Pardridge, W.M. Brain microvascular p-gp and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 2000, 20: 165-81.
64. Beaulieu, E., Demeule, M., Ghitescu, L., Beliveau, R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997, 326: 539-44.
65. Demeule, M., Labelle, M., Regina, A., Berthelet, F., Beliveau, R. Isolation of endothelial cells from brain, lung and kidney: Expression of the multidrug resistance p-glycoprotein isoforms. Biochem Biophys Res Commun 2001, 281: 827-34.
66. de Lange, E.C., de Bock, G., Schinkel, A.H., de Boer, A.G., Breimer, D.D. BBB transport and p-glycoprotein functionality using mdr1a (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm Res 1998, 15: 1657-65.
67. Ohnishi, T., Tamai, I., Sakanaka, K., Tamai, I., Tsuji, A. In vivo and in vitro evidence for ATP-dependency of p-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem Pharmacol 1995; 49: 1541-4.
68. Kusuhara, H., Sugiyama, Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part I). Drug Discov Today 2001, 6: 150-6.
69. Kusuhara, H., Sugiyama, Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part II). Drug Discov Today 2001, 6: 206-12.
70. Rao, V.V., Dahlheimer, J.L., Bardgett M.E. et al. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to blood-cerebrospinal-fluid drug permeability barrier. Proc Natl Acad Sci USA 1999, 96: 3900-5.
71. Pardridge, W.M., Frank, H.J.L., Cornford E.M., Braun L.D., Crane P.D., Oldendorf, W.H. Neuropeptides and blood-brain barrier. Adv Biochem Psychopharmacol 1981, 28: 321-8.
72. Keep, R.F., Jones, H.C. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Dev Brain Res 1990, 56: 47-53.
73. Tatsuta, T., Naito, M., Oh-hara, T., Sugawara, I., Tsuruo T. Functional involvement of p-glycoprotein in blood-brain barrier. J Biol Chem 1992, 267: 20383-91.
74. Tsuji, A., Tamai, I., Sakata, A. Restricted transport of cyclosporine A across the blood-brain barrier by a multidrug transporter, p-glycoprotein. Biochem Pharmacol 1993, 1096-9.
75. Shirai, A., Naito, M., Tatsuta, T. et al. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by p-glycoprotein. Biochem Biophys Acta 1994, 1222: 400-4.
76. Schinkel, A.H., Smit, J.J.M., van Tellingen, O. et al. Disruption of the mouse mdr la p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77: 491-502.
77. Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A., Borst, P. Absence of the mdr1a p-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995, 96: 1698-1705.
78. Schinkel, A.H., Mayer, U., Wagenaar, E. et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) p-glycoproteins. Proc Natl Acad Sci USA 1997, 94: 4028-33.
79. Polli, J.W., Jarrett, J.L., Studenberg, S.D. et al. Role of p-glycoprotein on CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999, 16: 1206-12.
80. Kim, R.B., Fromm, M.F., Wandel, C., Leak, B., Wood, A.J.J., Roden, D.M. The drug transporter p-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101: 289-94.
81. van Asperen, J., van Tellinge, O., Tijssen, F., Schinkel, A.H., Beijnen, J.H. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a p-glycoprotein. Br J Cancer 1999, 79: 108-13.
82. Yokogawa, K., Takahashi, M., Tamai, I. et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice. Pharm Res 1999, 16: 1213-8.
83. Yamazaki, M., Neway, W.E., Ohe, T. et al. In vitro substrate identification studies for p-glycoprotein mediated transport: Species and predictability of in vitro results. J Pharmacol Exp Ther 2001, 296: 723-35.
84. Schinkel, A.H., Wagenaar, E., Mol, C.A., van Deemter, L. P-glycoprotein in blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996, 97: 2517-24.
85. Choo, E.F., Leake, B., Wandel, C., Kim, R.B. Pharmacological inhibition of p-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000, 28: 655-60.
86. Mayer, U., Wagenaar, E., Dorobek, B., Benijnen, J.H., Borst, P., Schinkel, A.H. Full blockade of intestinal p-glycoprotein and extensive inhibition blood-brain barrier p-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997, 100: 2430-6.
87. Sadeque, A.J., Wandel, C., He, H. Increased drug delivery to the brain by p-glycoprotein inhibition. Clin Pharmacol Ther 2000, 68: 231-7.
88. Johanson, C.E. Ontogeny and phylogeny of the blood-barrier. In: Implications of the Blood-Brain Barrier and its Manipulation: Basic Science Aspects, vol. 1. Neuwelt, E.A. (Ed.). Plenum, New York 1988, Chapter 7: 157-98.
89. Begley, D.J., Khan, E.U., Rollinson, C., Abbott, J., Regina, A., Roux, F. The role of brain extracellular fluid production and efflux mechanisms in drug transport to the brain. In: The Blood-Brain Barrier and Drug Delivery to the CNS. Begley, D.J., Bradbury, M.W., Kreuter, J. (Eds.). Marcel Dekker, Inc., New York 2000, Chapter 6: 93-108.
90. Mahar Doan, K.M., Humphreys, J.E., Webster, L.O., Wring, S.A., Shampine, L.J., Serabjit-Singh C.J., Adkison, K.K., Polli, J.W. Passive permeability and p-glycoprotein mediated efflux differentiate CNS and non-CNS marketed drugs. J Pharmacol Exp Ther 2002, 303: 1029-37.
91. Roley M., Kulagowski J.J., Watt A.P. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J Med Chem 1997, 40: 4053-68.
92. Robinson, P.J., Rapoport, S.I. Kinetics of protein binding determines rates of uptake of drugs by brain. Am J Physiol 1986, 251: R1212-20.
93. Jones, D.R., Hall, S.D., Branch, R.A., Jackson, E.K., Wilkinson, G.R. Plasma binding and brain uptake of benzodiazepines. In: Protein Binding and Drug Transport. Tillement, J.P., Lindenlaub, E. (Eds.). F.K. Schattauer Verlag, New York 1986, 311-324.
94. Tanaka, H., Mizojiri, K. Drug-protein binding and blood-brain barrier permeability. J Pharmacol Exp Ther 1999, 288: 912-8.
95. Khaliq, Y., Gallicano, K., Venance, S. Effect of ketoconazole on ritonavir and saquinavir concentration in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2000, 68: 637-46.
96. 1-antagonists. Drug Metab Dispos 2003, 31: 312-8.
97. Adachi, Y., Suzuki, H., Sugiyama, Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 p-glycoprotein. Pharm Res 2001, 18: 1660-8.
98. Susanto, M., Benet, L.Z. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by p-glycoprotein transport? Pharm Res 2002, 19: 457-62.
99. Guo, A., Marinaro, W., Hu, P., Sinko, P.J. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing p-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 2002, 30: 457-63.
100. Ito, T., Yano, I., Tanaka, K., Inui, K. Transport of quinolone antibacterial drugs by human p-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther 1997, 282: 955-60.
101. Soldner, A., Benet, L.Z., Mutschler, E., Christians, U. Active transport of angiotensin-II antagonist losartan and its main metabolite EXP3174 across MDCKMDR1 and Caco-2 cell monolayers. Br J Pharmacol 2000, 129: 1235-43.
102. Karssen, A.M., Meijer, O.C., van der Sandt, I.J.C., De Boer, A.G., De Lange, E.C.M., De Kloet, E.R. The role of the efflux transporter p-glycoprotein in brain penetration of prednisolone. J Endocrinology 2002, 175: 251-60.
103. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Komano, T. Human p-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993, 268: 6077-80.
104. Duggan, D.E., Yeh, K.C., Matalia, N., Ditzler, C.A., McMahon, F.G. Bioavailability of oral dexamethasone. Clin Pharmacol Ther 1975, 18: 205-9.
105. Grujich, N.N., Gawel, M.J. Eltripan. Expert Opin Investig Drugs 2001, 10: 1869-74.
106. Terhaag, B., Donath, F., Petit, G., Feller, K. The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. Int J Clin Pharmacol Ther Toxicol 1986, 24: 298-302.